Physician profile
Usman Qureshi
NPI 1851365381
$542.69
in general payments reported to CMS, 2019-2025
14 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $25.56 · 2021: $44.00 · 2022: $31.52 · 2023: $110 · 2024: $46.76 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $129.54 | 2019-2023 | Xarelto |
| Pfizer INC. | $81.66 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $59.06 | 2023-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $44.35 | 2021-2023 | Verquvo |
| Medtronic, INC. | $34.55 | 2025 | Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.07 | 2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $26.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.88 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.27 | 2019 | |
| Cook Medical LLC | $20.86 | 2021 | |
| Abbott Laboratories | $19.65 | 2023 | Cardiomems |
| Gilead Sciences, INC. | $17.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.27 | 2024 | Jardiance |
| Cardiovascular Systems INC. | $9.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.